Bristol Myers Squibb stock gets USD 82.00 target from Piper Sandler

Published on 09/28/2026 at 15:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock delivered USD 2.04 EPS in Q2 2026, above USD 1.60 consensus. The company plans to report Q3 results on October 29, 2026, at 8:00 a.m. ET.

BMY, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb (ISIN US1101221083) was trading at USD 62.85 on the NYSE on September 28, 2026, at 9:40 a.m. ET, with a daily change of -0.02 percent. The latest analyst catalyst came on September 16, 2026, when Piper Sandler lifted its price target to USD 82.00 from USD 75.00 while keeping an Overweight rating, according to Investing.com.

USD 82.00 target sets the benchmark

The new target is USD 19.15 above the September 28 reference price, placing the price 23.35 percent below the target. Piper Sandler cited upcoming pivotal trial milestones involving milvexian, Cobenfy and admilparant as key considerations in its review.

The target change gives investors a concrete benchmark while the share price remains inside its current 52-week range of USD 42.52 to USD 68.64. The upper end is USD 5.79 above the reference price, leaving the market focused on whether pipeline progress can offset pressure on established medicines.

Q2 revenue rose 5.7 percent

Bristol Myers Squibb reported Q2 2026 EPS of USD 2.04, above the USD 1.60 consensus estimate, and revenue of USD 12.97 billion, up 5.7 percent from the same quarter a year earlier, according to MarketBeat. The company set fiscal 2026 EPS guidance at USD 6.75 to USD 7.00.

The Q2 figures provide the latest operating comparison for the stock. Revenue exceeded the USD 11.74 billion consensus estimate by USD 1.23 billion, while EPS beat consensus by USD 0.44, according to the same Q2 report.

October 29 brings the next test

Bristol Myers Squibb will report third-quarter 2026 results on October 29, 2026, with an investor conference call at 8:00 a.m. ET, according to the company's release dated September 18, 2026, published by Bristol Myers Squibb. That report will test whether the Q2 revenue growth and earnings beat can continue into the next period.

NYSE value and trading snapshot

Bristol Myers Squibb had a market capitalization of USD 128.4 billion and volume of 429,005 shares as of September 28, 2026. The stock's USD 62.85 reference price, NYSE listing and current 52-week range frame the valuation discussion around the USD 82.00 analyst target.